Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dirozalkib Phase I Study in ALK/ROS1+ NSCLC
NCT05055232Phase 1Completed
- Sponsor
- Xuanzhu Biopharmaceutical
- Start
- Mar 2019
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of dirozalkib in non-small cell lung cancer (NSCLC), sponsored by Xuanzhu Biopharmaceutical. Primary endpoints: Adverse Events and Serious Adverse Events, Dose Limiting Toxicities at 4 weeks and 1 more. Started Mar 2019; status: completed.
02
Drugs
dirozalkib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05055232.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05055232.